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Background: Antiretroviral therapy (ART) scale-up in resource-limited countries, with limited capacity for CD4 and
HIV viral load monitoring, presents a unique challenge. We determined the effectiveness of first-line ART in a real
world pediatric HIV clinic and explored associations between readily obtainable patient data and the trajectories of
change in CD4 count and HIV viral load.
Methods: We performed a longitudinal study of a cohort of HIV-infected children initiating ART at the Korle-Bu
Teaching Hospital Pediatric HIV clinic in Accra, Ghana, aged 0-13 years from 2009-2012. CD4 and viral load testing
were done every 4 to 6 months and genotypic resistance testing was performed for children failing therapy. A
mixed linear modeling approach, combining fixed and random subject effects, was employed for data analysis.
Results: Ninety HIV-infected children aged 0 to 13 years initiating ART were enrolled. The effectiveness of first-line
regimen among study participants was 83.3%, based on WHO criteria for virologic failure. Fifteen of the 90 (16.7%)
children met the criteria for virologic treatment failure after at least 24 weeks on ART. Sixty-seven percent virologic
failures harbored viruses with ≥ 1 drug resistant mutations (DRMs); M184V/K103N was the predominant resistance
pathway. Age at initiation of therapy, child’s gender, having a parent as a primary care giver, severity of illness, and
type of regimen were associated with treatment outcomes.
Conclusions: First-line ART regimens were effective and well tolerated. We identified predictors of the trajectories
of change in CD4 and viral load to inform targeted laboratory monitoring of ART among HIV-infected children in
resource-limited countries.
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There is an unprecedented global effort to scale-up anti-
retroviral treatment (ART) and provide universal access
to HIV care to all HIV-infected individuals. In resource-
limited settings, outcomes of pediatric HIV treatment
have been comparable to outcomes in resource-rich
countries [1,2]. Several studies from sub-Saharan Africa
have reported the effectiveness of ART using mortality* Correspondence: Elijah.paintsil@yale.edu
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reproduction in any medium, provided the oras an outcome among HIV-infected children [2-5].
Moreover, children receiving ART in resource-limited
settings have demonstrated low levels of drug toxicity,
with rates of adherence and retention similar to those in
resource-rich settings [3,4,6-8].
The success story of ART scale-up in resource-limited
countries presents a unique challenge with regard to
laboratory monitoring of treatment. The therapeutic
benefits of ART are often limited by long-term toxicities
and evolution of drug-resistant virus [9-11]. In resource-
rich countries, HIV treatment is monitored routinely
with laboratory measures such as blood chemistry, HIVd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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effects of medications and drug-resistant virus [12,13].
Due to the lack of accessible and affordable laboratory
services, routine laboratory monitoring is not feasible
in most resource-limited countries [14]. Without
laboratory monitoring, many patients may experience
prolonged virologic failure and develop drug resistance
mutations, which could ultimately limit second-line
treatment options, increase morbidity, mortality and
increase transmission of resistant viruses in the population
[5,15,16]. The World Health Organization (WHO) recom-
mends CD4 count monitoring every six months and viral
load testing only when the capacity exists. [17]. There are
limited data on laboratory monitoring of treatment from
real world pediatric HIV clinics in resource-limited
countries where there are frequent shortages of laboratory
reagents, breakdown of equipment in addition to poor
compliance with clinic appointments making testing at
fixed intervals impossible.
We recently reported that a targeted approach based on
predictors of CD4 recovery can be a viable and cost-
effective way of monitoring ART in HIV-infected children
in resource-limited settings [18]. To validate this finding,
we conducted a prospective observational longitudinal
study at Korle-Bu Teaching Hospital Pediatric HIV
Clinic. The main objectives of the current study
were: (1) to determine the real world effectiveness of
first line ART and pediatric care utilization; and (2)
to explore associations between readily obtainable




This was a single-center prospective observational longi-
tudinal study of HIV-infected children initiating ART at
the Pediatric HIV/AIDS Care program at Korle-Bu
Teaching Hospital in Accra, Ghana, from October 2009
to September 2012. The program currently cares for
over 1,100 children. The first-line regimen available at
the clinic is non-nucleoside analog (NNRTI)-based ART
consisting of zidovudine (ZDV) plus lamivudine (3TC),
plus either nevirapine (NVP) or efavirenz (EFV). Written
consents from parents or guardians and assents from
children were obtained before enrollment in the study.
The study was reviewed and approved by the Ethics and
Protocol Review Committees of University of Ghana
Medical School and Yale School of Medicine.
At the time of enrollment, participants and guardians
were interviewed to collect demographic and back-
ground information and their medical records were
reviewed. The participants were seen and examined at
the pediatric HIV clinic every 4-6 months, and more fre-
quently as necessary, in accordance with local standard-of-care. CD4 cell count/percentage and HIV viral load
determinations were done every 4-6 months. Adher-
ence was determined by caregivers report and catego-
rized according to WHO guidelines: adherence is said
to be “good adherence” (i.e., missing ≤3 doses in a
month, ≥95%), “fair adherence” (i.e., missing 4-8 doses
in a month, 85%-94%), and “poor adherence” (i.e., miss-
ing ≥9 doses in a month, <85%) [19]. The study’s main
outcome variables were CD4 absolute count, CD4 per-
centage and viral load over the study period.
WHO definitions for treatment failure in HIV-infected
children on ART
Clinical failure is defined as the appearance or re-
appearance of WHO clinical stage 3 or stage 4 events
after at least 24 weeks on ART in a treatment-adherent
child. Immunological failure is defined as developing or
returning to the following age-related immunological
thresholds after at least 24 weeks on ART, in a
treatment-adherent child: (1) CD4 count of <200 cells/μL
or percent CD4 <10% for a child ≥2 years to <5 years of
age, (2) CD4 count of <100 cells/ μL for a child 5 years of
age or older. Virologic failure is defined as a persistent
HIV viral load of ≥ 5,000 copies/ml, after at least 24 weeks
on ART, in a treatment-adherent child [19]. Based on
the definitions of treatment failure above, ART treat-
ment is deemed effective if none of the clinical, im-
munological or virologic criteria for failure are met
after at least 24 weeks on ART. However, for purposes
of this study, the definition of effectiveness is based on
the virologic criteria for failure because it the most sen-
sitive. Therefore treatment effectiveness was defined as
HIV viral load <5,000 copies/ml after at least 24 weeks
on ART.
Other study measure
CD4 cell count and HIV viral load measurements
CD4 absolute cell count and cell percentage were quan-
tified by a dual-platform flow cytometry technology
using a FACSCount system (Becton-Dickinson, Franklin
Lakes, NJ, USA) at the clinical laboratory at Korle-Bu
Teaching Hospital (KBTH) according to manufacturer’s
instructions. The HIV RNA viral load testing was
performed using the COBAS ® AMPLICOR Monitor test
(Roche Diagnostic Systems, Branchburg, NJ, USA). The
limit of HIV-1 RNA detection was 50 copies/mL. The la-
boratory is certified by the South African Public Health
Reference Laboratory and participates in an external
quality assurance testing program by the South African
Public Health Reference Laboratory.
HIV sequencing and mutational analyses
HIV genotyping was performed at Noguchi Memorial
Institute of Medical Research (NMIMR), University of
Table 1 Characteristics of study population;
N = 90 children
Characteristic
(categorical variables)







Age at ART Initiation
< 2 years 14 (15.6%)
[2-5) years 25 (27.8%)
≥ 5 years 51 (56.7%)
ART Regimen
3TC, ZDV, EFV 66 (73.3)
3TC, ZDV, NVP 18 (20.0)
Other 6 (6.7)











Min, Max, Q1, Median Q3
Age at ART Initiation (months) 1.0 153.6 44.4 70.6 107.2
Number of Available Visits During
Study Period
1 9 3 4 6
Time Between ART Initiation and
First Available Visit (months)
0.0 8.5 0.4 1.4 3.0
Time Between ART Initiation and
Last Available Visit (months)
0.0 32.0 10.0 16.0 21.0
CD4 Labs at First Available Visit
Post ART Initiation
Absolute Count (cells/μL) 9.0 3,293 339.0 663.0 1,075
Log(Absolute Count) 2.2 8.1 5.8 6.5 7.0
Percentile 0.0 50.5 10.3 16.9 26.6
Viral Load at First Available Visit
Post ART Initiation
Viral Load (Copies/mL) 63.0 3.6 ×
106
400.0 463.0 10,600
Log (Viral Load) 4.1 15.1 6.0 6.1 9.3
Abbreviations: ART Antiretroviral Therapy, 3TC Lamivudine, ZDV Zidovudine,
NVP Nevirapine, EFV Efavirenz, WHO World Health Organization,
TB Tuberculosis.
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ase chain reaction (PCR) protocol. The reverse transcript-
ase (RT) and protease (PR)-coding regions were amplified
in separate reactions using gene-specific primers and one-
step RT-PCR techniques previously published [20]. The
sequence data were assembled and edited using SeqMan
(DNASTAR, USA). The FASTA-formatted sequences
were then submitted online to the Stanford University
HIVDR Database (http://hivdb.stanford.edu) to generate a
mutation list and subtype information. The resulting mu-
tation list was compared with the WHO mutation lists for
HIVDR surveillance [21,22]. HIV-1 drug susceptibility of
participants’ genotype was predicted using the Stanford al-
gorithm, version 6.1.0 (http://hivdb.stanford.edu).
Statistical analysis
Descriptive statistics, such as counts, percents and quar-
tiles were used to summarize characteristics of children
in the study. CD4 absolute counts and viral loads were
log-transformed prior to statistical modeling. Linear
mixed effects modeling was the primary statistical ana-
lysis. Along with such fixed effects as child’s gender, pri-
mary caregiver status, ART regimen and WHO HIV
clinical staging, a random intercept with unstructured
covariance was included. This allowed each child to have
his/her specific constant variation around the group
means. Intra-class correlation (ICC) for each outcome of
interest was calculated to quantify the variability in the
observed data due to individual child.
Longitudinal analyses were performed using mixed
models to examine differences in CD4 cell count, CD4
percentage and HIV viral load by gender, WHO clinical
staging and other demographic characteristics. Mixed
model analysis was used as this approach does not re-
quire all participants to have the same number of mea-
surements and uses all available outcome data, thus
providing an unbiased estimate of the model parameters,
given that missing outcomes are missing at random
(MAR). Under the MAR assumption we expect that the
missing outcomes are only dependent on the observed
data and not on the unobserved data [23]. Along with
the fixed linear and quadratic terms for time, a random
subject-specific intercept, and an initial covariance set at
Compound Symmetry (CS), each fixed factor was tested
independently, with or without its interaction with the
time terms. The best covariance structure was deter-
mined using the likelihood ratio test or Akaike Informa-
tion Criterion (AIC), as appropriate. Findings are
presented as parameter estimates from the mixed effects
models, interpretable as the change in the average level
of the outcome of interest (conditional on the random
effect) for every 1 unit increase in the predictor variable
for continuous predictors, or as the difference in the
outcome of interest between a level of a predictor and a
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were performed using SAS 9.2 (Cary, NC).
Results
Baseline characteristics of study population
Ninety HIV-infected children aged 0 to 13 years initiating
ART were enrolled to the study between October 2009 and
September 2012. The number of available visits ranged
between 1 and 9, with a median of 4 visits. This cor-
responded to a median of 16 months of follow-up (ranging
from 0 to 32 months). Table 1 summarizes demographic and
clinical characteristics of study participants. There were 53
males (59%), with over half of the children still living with
their biologic parents (66.3%). Over half of children started
ART at 5 years old or older and more than a quarter of the
participants had a previous tuberculosis (TB) diagnosis.
Effectiveness of first-line ART regimens
The effectiveness of first-line regimen among study par-




Age at ART Initiation (months) -0.02 (0.00







WHO HIV Clinical Stage -0.2 (0.2)
ART Therapy
3TC, ZDV, EFV 0.1 (0.3)
Other -0.01 (0.4)
3TC, ZDV, NVP (Reference)
Time Post Initiation of ART Therapy (months) -0.10 (0.06
Squared Time Post Initiation of ART Therapy (months) 0.004 (0.0
Interaction Between Time and Age at ART Initiation 0.001 (0.0
Interaction Between Squared Time and Age at ART Initiation -0.3-4 (0.1
Interaction Between Time and Female Gender 0.05 (0.03
Interaction Between Squared Time and Female Gender -0.002 (0.0
Interaction Between Time and WHO HIV Clinical Stage 0.04 (0.02
Interaction Between Squared Time and WHO HIV Clinical Stage -0.001 (0.0
Interaction between Time and Number of Visits -
Interaction Between Squared Time and Number of Visits -
Abbreviations: ART Antiretroviral Therapy, 3TC Lamivudine, ZDV Zidovudine, NVP Ne
*Log-transformed for analysis.failure. Fifteen of the 90 (16.7%) children met the WHO
virologic criteria for treatment failure, i.e., HIV RNA of ≥
5,000 copies/ml after at least 24 weeks on ART [19].
The median time to virologic failure was 7.8 months
(range, 5.5 to 27.6 months). Interestingly, only two of
the virologic failures met the WHO criteria for immuno-
logic failure. There were neither mortalities nor lost to
follow-up during the duration of the study. Three partic-
ipants switched ARV regimen (3.3%). Two participants
switched due to NVP toxicity (generalized rash and un-
specified toxicity) and one due to interaction with anti-
TB medications. For participants with at least 24 months
of follow-up, 71% of these children had undetectable
viral loads (HIV RNA <400 copies/ml).
Longitudinal modeling of CD4 cell count (absolute and
percentage) and HIV viral outcomes
Since our setting reflects real world pediatric HIV care
where laboratory measures are sparse and usually miss-
ing at random (MAR, i.e., the likelihood of an outcomelute count*, ICC(%) = 0.65 CD4 Percentage*, ICC(%) = 60.5
r Estimate (SE) p-value Parameter Estimate (SE) p-value
<0.0001 20.7 (5.1) 0.0001
3) <0.0001 -0.11 (0.01) 0.0004
) 0.32 0.93 (0.7) 0.15
0.85 2.2 (2.0) 0.29
0.07 1.4 (2.2) 0.52
0.15 -1.5 (1.1) 0.18
0.66 2.7 (3.0) 0.38
0.98 -4.0 (4.9) 0.41
) 0.09 3.6 (0.7) <0.0001
02) 0.07 -0.12 (0.03) 0.0003
004) 0.01 - -
-4) 0.03 - -
) 0.11 - -
01) 0.06 - -
) 0.05 - -
007) 0.09 - -
- -0.39 (0.11) 0.0003
- 0.01 (0.005) 0.0018
virapine, EFV Efavirenz, WHO World Health Organization.
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be explained by the observed data), we modeled the
CD4 and HIV viral load outcomes. At first available visit,
absolute CD4 count ranged between 9 and 3,293 cells/
μL, corresponding to 2.2-8.1 on the log scale. CD4 per-
centage ranged between 0% and 50.5%, and viral load
was at a minimum of 63 copies/mL in some children
and at a maximum of 3.6 × 106 copies/mL in others.
CD4 Absolute Count
Table 2 provides a summary of the final model for CD4
cell count. There was a statistically significant increase
in the level of CD4 absolute count on the log-scale
across time. The increase was not just linear but also
quadratic; that is, as the duration of follow-up increased,
the CD4 absolute count leveled off. While older age at
ART initiation, greater number of available visits duringA
C
Figure 1 Correlates of longitudinal changes in CD4 absolute count amo
2009 to 2012. CD4 count was log-transformed for statistical modeling. (A) Ef
CD4 trajectory. (C) Effect of WHO Clinical Staging at HIV diagnosis on CD4 trafollow-up, female gender, and having more severe WHO
HIV clinical staging were all negatively associated with
the level of CD4 absolute count on the log-scale, only
age at ART initiation reached statistical significance. There
were statistical trends for some interactions (Figure 1): (1)
females showed a somewhat greater initial slope in the
positive change of the outcome over time, but that was
mitigated by the negative quadratic slope, resulting in
males catching up with girls as the duration of follow-up
increased; (2) children with lower WHO HIV clinical sta-
ging had on average higher CD4 absolute counts, their
rate of increase over time was slower than among children
with more severe HIV stage; and (3) children whose pri-
mary caretakers were their biological parent(s) had overall
greater counts, as well as a higher rate of increase than
children who were taken care of by non-biological par-
ents. Of note, there was no statistically significantB
D
ng HIV-infected children on antiretroviral therapy in Ghana from
fect of gender on CD4 trajectory. (B) Effect of age at ART initiation on
jectory. (D) Effect of primary care giver of child on CD4 trajectory.




Intercept 8.1 (1.2) <0.0001
Age at ART Initiation (months) 0.004 (0.005) 0.45




Female 1.3 (0.7) 0.06
Male (Reference)
Primary Caregiver
Parent -0.03 (0.4) 0.94
Other (Reference)
WHO HIV Clinical Stage 0.3 (0.2) 0.15
ART Therapy
3TC, ZDV, EFV -1.1 (6) 0.05
Other -0.5 (0.9) 0.61
3TC, ZDV, NVP (Reference)
Time Post Initiation of ART
Therapy (months)
-0.6 (0.2) 0.002
Squared Time Post Initiation of
ART Therapy (months)
0.02 (0.01) 0.02




Time and Female Gender
0.005 (0.004) 0.23




Time and Number of visits
-0.003 (0.001) 0.02
Abbreviations: ART Antiretroviral Therapy, 3TC Lamivudine, ZDV Zidovudine,
NVP Nevirapine, EFV Efavirenz, WHO World Health Organization.
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to type of ART regimen.
CD4 Percentages
The only significant changes in CD4 percentage over the
follow-up period were attributable to the age at initiation
of ART therapy and the number of available follow up
visits (Table 2). Similar to the finding for the trajectory
of change in CD4 absolute counts, younger age at initi-
ation was associated with overall higher CD4 percentage
during the follow-up time, however we did not observe a
differential rate of change over time in CD4 percentage
due to the age of ART therapy initiation.
HIV Viral Load
The rate of decrease in HIV viral load slowed over time.
Table 3 provides a summary for this analysis. While females
had higher HIV viral loads initially as compared to males,
their rate of decline in HIV copies/mL on the log scale was
significantly faster (Figure 2A). There was a significant dif-
ference in the trajectories of change in the viral load among
the ART regimens: compared to 3TC+ZDV+NVP, children
on 3TC+ZDV+EFV had on average lower levels of HIV
viral load (Figure 2B). Children with 6-8 number of visits
had the highest overall level and the slowest rate of decline
in viral loads, compared to children with fewer visits
(Figure 2C). In general, the slope of decline was steepest
over the first 10 months after initiation of treatment.
HIV drug resistance prevalence and pattern among
virologic failures
The median time to virologic failure was 7.8 months. Of
the 15 children meeting criteria for virologic failure, se-
quence results were available for 12 (80%); we were not
successful in amplifying DNA from three of the failures.
Eight of the 12 children (67%) harbored drug resistant
mutations (DRMs) and four (33%) did not harbor any
DRMs (Table 4). Sixty-seven percent of children had
mutations associated with NRTI, NNRTI, or both NRTI
and NNRTI. Of the NRTI-associated DRMs, M184V
was the most frequent (8 of 8, 100%). Thymidine-
associated mutations (TAMs) were rare with only one
patient (1 of 8, 12.5%) harboring T215Y mutation in
combination with M184V. Of the NNRTI-associated
mutations, K103N (6 of 8, 75%) was the most frequent,
followed by Y181C/H (3 of 8, 37.5%). K103N and Y181C
were the most frequent NNRTI mutations in patients on
EFV- and NVP-based regimens, respectively. M184V
and K103N were present in combination in 50% of the
patients with DRMs.
The second-line regimen widely available in the clinic
is 3TC, abacavir (ABC), and lopinavir/ ritonavir. We in-
vestigated the susceptibility of the genotypes at virologic
failure to second-line regimen. Of the 12 out of the 15failures with successful genotypic data, susceptibility to
3TC and emtricitabine (FTC) was reduced in 66.7% of
the subjects (data not shown). Susceptibility to ABC, the
second nucleoside analog of the second-line regimen,
was potentially reduced in 75% of subjects. For the other
NRTIs (ZDV, d4T, ddT, and TDF), susceptibility was still
at 91.7%. All the children were still susceptible to
ritonavir-boosted protease inhibitors (PIs).
Discussion
Our study demonstrates the effectiveness of NNRTI-
based first-line regimens used at Korle-Bu Teaching
Hospital for HIV-infected children. For 83.3% of the
study participants, the first-line ART regimen was ef-
fective. At 24 months of follow-up, about 71% of our par-
ticipants had viral load <400 copies/ml. Both absolute
CD4 cell counts and CD4 cell percentages demonstrated a
sustained immunologic response through 24 months of
A B
C
Figure 2 Correlates of longitudinal changes viral load among HIV-infected children on antiretroviral therapy in Ghana from 2009 to
2012. Viral load was log-transformed for statistical modeling. (A) Effect of gender on viral load trajectory. (B) Effect of type of ART regimen on
viral load trajectory. (C) Effect of number of clinic visits since ART initiation on viral load trajectory.
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with reports of effectiveness of ART in HIV-infected chil-
dren from other countries in sub-Saharan Africa [2-5].
Furthermore, we found high tolerance of the first-line
ART regimen in our population based on the low levels
of toxicity, and fewer regimen switches. Our rates of
regimen switching and toxicity are comparable to previ-
ous studies in the region and in other resource-limited
settings [4,6]. There were no deaths among the children
during the study period. Most importantly, our rates of
effectiveness, toxicity, and mortality are comparable to
that reported among HIV-infected children in resource-
rich countries. Therefore, the unprecedented global ef-
fort at scaling up HAART in resource-limited countries
is paying off.
The rate of virologic treatment failure after at least
24 weeks was 16.7% among our study participants on theirfirst-line regimen. This is consistent with previously
reported rates in pediatric HIV cohorts from the sub-
region ranging from 13% to 44% [24-26]. First, consistent
with other reports, we found low sensitivity of clinical and
immunologic monitoring for detecting virologic treatment
failure resulting in HIV drug resistance [27-30]. Interest-
ingly, only two of the virologic failures would have been
captured by the WHO criteria for either immunologic or
clinical failure – the gold standard for detection of treat-
ment failure [31]. Second, consistent with limited number
of studies on early virologic failure in children in sub-
Saharan African, the median time to virologic treatment
failure in our cohort was 7.8 months (range, 5.5 to
27.6 months) [24,25,30]. Adje-Toure et al found that 58%
of a cohort of children in Abidjan with detectable viral
load after three to five months on therapy harbored HIV
DRMs [25]. Therefore, if decisions regarding treatment
Table 4 HIV drug resistance prevalence and pattern
among HIV-infected children failing HAART in Ghana
(N = 12)
Resistance category Patients, N (%)
No drug resistance 4 (33)
Resistance to any class 8 (67)
Resistance to NRTI 8 (67)
Resistance to NNRTI 8( 67)
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most of these children could accumulate multiple DRMs
before they are switched to a second-line regimen. Taken
together, in the absence of routine virologic testing, HIV-
infected children starting ART are at risk for undetectable
virologic failure with concomitant development of mul-
tiple DRMs that will limit their options for effective
second-line regimens.
At virologic failure, 67% of the children harbored viruses
with ≥ 1 DRMs, and dual-class resistance was observed in
50% with M84V/K103N being the predominant resistance
pathway. Most importantly, our study adds to the limited
data on the contribution of early virologic failure to evolu-
tion of DRMs in HIV-infected children in sub-Saharan
Africa [25]. Furthermore, we observed that the pattern
and evolution of resistance mutations is consistent with
the components of the first-line regimen as previously
reported [24,25,32]. This is valuable information fortreatment programs in resource-limited countries in
procurement of first- and second-line regimens. Our
findings and that of others underscore the urgent need
for implementation of viral load monitoring of HIV
treatment programs in sub-Saharan Africa to prevent
accumulation of DRMs [28,33].
The arguments against routine use of laboratory moni-
toring in resource-limited settings are sustained by con-
sideration of cost, technical expertise, and lack of
infrastructure [34]. While efforts at developing low-cost
technologies continue, the question to be answered is:
can we adopt a less frequent and targeted testing sched-
ule for CD4 and viral load monitoring? To answer this
question, we explored whether readily obtainable data
on patients’ characteristics could predict the trajectories
of change in CD4 absolute count, CD4 percentage, and
HIV viral load. Thus, these predictor variables could in-
form targeted monitoring strategies. Following ART ini-
tiation, we observed a statistically significant increase in
CD4 absolute count and CD4 percentage over time.
However, the trajectories with time were not linear; they
leveled off over time. There was a great degree of vari-
ability among children, as expressed by 65% and 61%
ICC for CD4 absolute counts and percentages, respect-
ively, supporting the inclusion of the random effect in
the model. There were differences in terms of predictors
of CD4 absolute counts vs. CD percentages. The nega-
tive quadratic slope observed for children with more se-
vere WHO clinical stages suggests a significant slowing
in the increase in CD4 absolute counts for that group.
This suggests that immune reconstitution may not be
robust and complete in severely immuno-compromised
HIV-infected children initiating ART. To our surprise,
gender and caregiver status played important roles in
CD4 absolute count trajectory. Having a biologic parent
as a primary caregiver was positively associated with
gains in CD4 absolute count. This can be attributed to
the benefits of having a stable family with more consist-
ent routines, as compared to losing a parent and having
a child’s life disrupted. Female children had better CD4
trajectory. We previously reported that female gender
was associated with faster CD4 recovery after initiation
of ART [18]. Moreover, a recent Thai study reported
that female children had a better immunologic and viro-
logic response than males [35]. There are no reports on
association between CD4 recovery or trajectory and gen-
der in pediatrics from sub-Saharan Africa, with the ex-
ception of one study that found male gender to be
associated with virologic failure [36]. The reasons for
this gender effect are not well understood. Interestingly,
in HIV-infected adults, gender differences in treatment
outcome (i.e., immunologic and virologic) have received
mixed reviews [37,38]. The trajectory of change in HIV
viral load was a negative reflection of the CD4
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having higher viral loads, but their rate of decrease over
time was significantly greater than that of the male chil-
dren. The role of gender in HIV treatment outcome is
very intriguing and needs further investigation.
There are certain limitations to our study. First, this is
a single center study and, therefore, one has to be cau-
tious in generalization of our findings. Moreover, the
limitations of this analysis include having a relatively
small sample size for an observational longitudinal ana-
lysis. However, some of the limitations reflect realities in
carrying out such a study in a resource-limited setting.
At the same time, an important strength of our study is
the setting of a real world pediatric HIV clinical care in
a resource-limited country with all the perennial la-
boratory capacity challenges that could represent an
overwhelming majority of pediatric HIV clinics in sub-
Saharan Africa.
Conclusions
In conclusion, our study demonstrates that available
first-line ART regimens at Korle Bu Teaching Hospital
in Accra, Ghana are effective and well tolerated. We also
identified important predictors of the trajectories of
change in CD4 and viral load after ART initiation, which
can inform further studies and feasible targeted labora-
tory monitoring of ART among HIV-infected children in
resource-limited countries. Furthermore, our findings
support the scale-up of universal access to the current
ART regimens. However, the scale-up should be concur-
rent with the use of innovative and low cost technologies
for laboratory monitoring of ART as the proportion of
children with early virologic failure and DRMs is not
trivial and is of public health concern. National pro-
grams should invest in laboratory capacity to provide at
least targeted CD4 and viral load monitoring.
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